Trial: 202007156

A Phase 4, single-arm, open-label clinical study of pembrolizumab (MK-
3475) to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTEB10).

Phase

IV (Cancer Control)

Principal Investigator

Oppelt, Peter

Disease Site

Larynx; Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov